PMID- 20964470 OWN - NLM STAT- MEDLINE DCOM- 20110203 LR - 20211020 IS - 1936-2692 (Electronic) IS - 1088-0224 (Print) IS - 1088-0224 (Linking) VI - 16 IP - 10 DP - 2010 Oct TI - Variation in prescription use and spending for lipid-lowering and diabetes medications in the Veterans Affairs Healthcare System. PG - 741-50 AB - OBJECTIVES: To examine variation in outpatient prescription use and spending for hyperlipidemia and diabetes mellitus in the Veterans Affairs Healthcare System (VA) and its association with quality measures for these conditions. STUDY DESIGN: Cross-sectional. METHODS: We compared outpatient prescription use, spending, and quality of care across 135 VA medical centers (VAMCs) in fiscal year 2008, including 2.3 million patients dispensed lipid-lowering medications and 981,031 patients dispensed diabetes medications. At each facility, we calculated VAMC-level cost per patient for these medications, the proportion of patients taking brand-name drugs, and Healthcare Effectiveness Data and Information Set (HEDIS) scores for hyperlipidemia (low-density lipoprotein cholesterol level <100 mg/dL) and for diabetes (glycosylated hemoglobin level >9% or not measured). RESULTS: The median cost per patient for lipid-lowering agents in fiscal year 2008 was $49.60 and varied from $39.68 in the least expensive quartile of VAMCs to $69.57 in the most expensive quartile (P < .001). For diabetes agents, the median cost per patient was $158.34 and varied from $123.34 in the least expensive quartile to $198.31 in the most expensive quartile (P < .001). The proportion of patients dispensed brand-name oral drugs among these classes in the most expensive quartile of VAMCs was twice that in the least expensive quartile (P < .001). There was no correlation between VAMC-level prescription spending and performance on HEDIS measures for lipid-lowering drugs (r = 0.12 and r = 0.07) or for diabetes agents (r = -0.10). CONCLUSIONS: Despite the existence of a closely managed formulary, significant variation in prescription spending and use of brand-name drugs exists in the VA. Although we could not explicitly risk-adjust, there appears to be no relationship between prescription spending and quality of care. FAU - Gellad, Walid F AU - Gellad WF AD - Center for Health Equity Research and Promotion, VA Pittsburgh Healthcare System, Pittsburgh, PA 15206, USA. walid.gellad@va.gov FAU - Good, Chester B AU - Good CB FAU - Lowe, John C AU - Lowe JC FAU - Donohue, Julie M AU - Donohue JM LA - eng GR - KL2 RR024154/RR/NCRR NIH HHS/United States GR - KL2 RR024154-01/RR/NCRR NIH HHS/United States GR - KL2 TR000146/TR/NCATS NIH HHS/United States PT - Comparative Study PT - Journal Article PT - Research Support, N.I.H., Extramural PT - Research Support, U.S. Gov't, Non-P.H.S. PL - United States TA - Am J Manag Care JT - The American journal of managed care JID - 9613960 RN - 0 (Hypoglycemic Agents) RN - 0 (Hypolipidemic Agents) RN - 0 (Prescription Drugs) MH - Confidence Intervals MH - Cross-Sectional Studies MH - Diabetes Mellitus/drug therapy/*economics MH - Economics, Pharmaceutical MH - Health Care Costs MH - Health Expenditures MH - Hospitals, Veterans/*economics/statistics & numerical data MH - Humans MH - Hyperlipidemias/*drug therapy/economics MH - Hypoglycemic Agents/*economics/therapeutic use MH - Hypolipidemic Agents/economics/*therapeutic use MH - Logistic Models MH - Odds Ratio MH - Outpatients/statistics & numerical data MH - Prescription Drugs/*economics MH - Statistics, Nonparametric MH - United States MH - United States Department of Veterans Affairs PMC - PMC3096004 MID - NIHMS285336 EDAT- 2010/10/23 06:00 MHDA- 2011/02/04 06:00 PMCR- 2011/05/17 CRDT- 2010/10/23 06:00 PHST- 2010/10/23 06:00 [entrez] PHST- 2010/10/23 06:00 [pubmed] PHST- 2011/02/04 06:00 [medline] PHST- 2011/05/17 00:00 [pmc-release] AID - 12725 [pii] PST - ppublish SO - Am J Manag Care. 2010 Oct;16(10):741-50.